<DOC>
	<DOCNO>NCT02491541</DOCNO>
	<brief_summary>The purpose single-centre , randomize , double-blind , parallel control , phase 3 study evaluate safety immunogenicity rabies vaccine ( Vero Cell ) human use healthy Chinese subject age 10-60 year , accord Essen method ( 1-1-1-1-1 ) vaccination .</brief_summary>
	<brief_title>A Phase 3 Clinical Trial Rabies Vaccine ( Vero Cell ) Human Use Healthy Chinese Subjects</brief_title>
	<detailed_description>There two immunization arm . 1200 healthy subject randomly assign ( 1:1 ) receive experimental vaccine parallel comparator vaccine . All receive five dos rabies vaccine day 0,3,7,14,28 accord traditional Essen method ( 1-1-1-1-1 ) vaccination .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 10 60 year old Subjects legal guardian comply requirement protocol Subjects legal guardian able understand sign inform consent Healthy subject judged medical history investigator 's inquiry Subjects temperature &lt; =37.0Â°C axillary set Female lactation pregnancy , plan pregnant study period Subject allergic history vaccine medicine Subject injury history dog mammal vaccinate rabies vaccine Subject serious adverse reaction history vaccination allergy , hive , difficulty breathing , angioedema abdominal pain Subject congenital malformation , developmental disorder serious chronic disease Subject autoimmune disease immunodeficiency Subject asthma , unstable past two year require emergency treatment , hospitalization , intubation , oral intravenous corticosteroid Subject diabetes ( Type I II ) exclude gestational diabetes Subject thyroidectomy history , require treatment past 12 month due thyroid disease Subject severe angioedema past 3 year require treatment past 2 year Subject hypertension blood pressure exceed 145/95 mmHg enrollment time Subject coagulation abnormality diagnose doctor ( clot factor deficiency , coagulation disorder , platelet disorder ) obvious bruise blood clot disorder Subject cancer , treat active cancer period clearly cure , may recur study period Subject epilepsy , exclude alcohol epilepsy within three year quit drink need treatment past 3 year Asplenia , functional asplenia , without spleen removal spleen cause situation GuillainBarre syndrome Any prior administration immunodepressant corticosteroid last 6 month Any prior administration blood product last 3 month Any prior administration research medicine/vaccine last 30 day Any prior administration attenuate live vaccine last 30 day Any prior administration subunit inactivate vaccine last 14 day , pneumococcal vaccine Ongoing antituberculosis prevention treatment Subject comply trial requirement , mental illness/ dualstage affective psychosis past present ; control need take psychiatric drug past 2 year ; suicidal tendency past 5 year Any medical , psychological , social condition judge investigator , may interfere subject 's compliance protocol signature inform consent</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>